No surrogate in toxicology; the clinical antibody was tested in cynomolgus monkeys (mouse anti-IL-31RA BM095 used only in an AD mouse pharmacology model)
“In addition, by using a mouse surrogate anti-IL31RA monoclonal antibody (BM095) the effect of blocking IL-31RA in a mite antigen-induced AD mouse model was evaluated.”
Cynomolgus monkey: fertility endpoints in 6-month toxicity study; EFD, pre/postnatal and juvenile in ePPND study
“Safety pharmacology endpoints and fertility assessment were incorporated into the 6-month repeat-dose toxicity study. Embryofetal development, pre- and postnatal development, and juvenile toxicity were evaluated in the ePPND study.”
Not conducted; ECAC concurred that carcinogenicity studies are not needed
“The Executive Carcinogenicity Assessment Committee provided concurrence on 02/13/2018 that carcinogenicity studies are not needed to support the development of nemolizumab.”